TRIPLE NEGATIVE BREAST CANCER

This study tested a combination of two drugs (sintilimab and anlotinib) plus standard chemotherapy given before surgery to people with early-stage triple-negative breast cancer. The goal was to see if this approach could eliminate all signs of cancer by the time of surgery. 29 pa…

This study tested a combination of two drugs, crizotinib and fulvestrant, in 33 people with advanced lobular breast cancer or other cancers linked to a CDH1 gene mutation. The goal was to see if the treatment could shrink tumors and to check for side effects. While both drugs had…

This early-phase study tested a new experimental drug called HMBD-002, alone or with another cancer drug (pembrolizumab), in 48 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see …

This study tested a combination of two drugs (NT-I7 and pembrolizumab) in 215 adults with advanced solid tumors that had come back or stopped responding to standard treatments. The goal was to find a safe dose and see if the combo could shrink tumors. The study also looked at imm…

This early-phase study tested whether giving an immune-boosting treatment called IRX-2 before chemotherapy is safe for people with early-stage breast cancer. Sixteen participants received IRX-2 before their planned chemotherapy and surgery. The main goal was to check for any trea…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced cancers that had stopped responding to standard treatments. The cancers included triple-negative breast, ovarian, gastric, colorectal, glioblastoma, biliary tract, and pancreat…

This study tested whether adding the immunotherapy drug toripalimab to standard chemotherapy (nab-paclitaxel) helps people with metastatic or recurrent triple-negative breast cancer live longer without their cancer growing. About 531 participants received either the combination o…

This study tested a new drug (TJ004309) combined with an approved immunotherapy (atezolizumab) in 25 people with advanced ovarian, head and neck, lung, gastrointestinal, or triple-negative breast cancers. The goal was to see if the combination could shrink tumors. Participants ha…

This study tested a specific sequence of chemotherapy drugs given before surgery to women with triple-negative breast cancer, a type that is harder to treat. The goal was to see if the treatment could completely eliminate cancer from the breast and lymph nodes. 29 women participa…

This study tested the safety of combining the immunotherapy drug atezolizumab with the chemotherapy nab-paclitaxel in 184 people with advanced triple-negative breast cancer that had a specific protein (PD-L1). Participants had not received chemotherapy for their advanced disease.…

This study tested a new radioactive tracer called 89Zr-TLX250 that attaches to a protein (CAIX) found on some triple negative breast cancer cells. Twelve people with advanced triple negative breast cancer received the tracer and had a PET/CT scan. The researchers compared how man…

This study tested whether adding two supportive drugs (loperamide for diarrhea and G-CSF for low white blood cells) could make a common chemotherapy drug, sacituzumab govitecan, easier to tolerate. It involved 50 adults with advanced triple-negative or luminal breast cancer that …

This study looked at 49 women with triple negative breast cancer to see if the bacteria in their gut and tumors affected how well chemotherapy worked. Researchers collected samples before and during treatment to find links between certain bacteria and a complete response (no canc…

This study tested a new lab test (RAD51-foci) to see if it can predict whether the drug olaparib will shrink tumors in people with advanced HER2-negative breast cancer who have certain gene mutations (BRCA1, BRCA2, PALB2, RAD51C, or RAD51D). The study involved 65 participants and…

This study tested two chemotherapy drugs, cisplatin and paclitaxel, given before surgery to 147 people with triple negative breast cancer. The goal was to see if a test measuring DNA repair problems (HRD) could predict which drug would work better. Results help doctors understand…

This study aimed to create a communication tool to help doctors and patients talk about cancer that stops responding to treatment. Researchers interviewed 128 people, including patients with certain breast cancers, metastatic uveal melanoma, and parents of children with cancer, a…

This study looked at whether adding a breast MRI before surgery helps women with early-stage breast cancer have better results. About 317 women with certain types of breast cancer took part. The goal was to see if the MRI helps doctors choose the best surgery and reduce the need …